Appendix 4C - Quarterly Cashflow
Filed with ASX · · 9 pages · English
Sydney, Australia - 28 April 2016: OncoSil Medical Ltd (ASX: OSL) (Oncosil or the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer, today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 31 March 2016 (the Quarter). All financial results are in Australian dollars and are unaudited. Highlights for
Earlier from OncoSil Medical
- Oncosils next generation delivery platform
- $10 Million Institutional Placement
- US FDA Investigational Device Exemption submitted
Later from OncoSil Medical
- OncoSil Medical Appoints Global Sales and Marketing Director
- Regulatory Update June 2016
- FDA IDE Approval
- Hot Calibration Run of the OncoSil Device
- Appendix 4E - Preliminary final report 30 June 2016
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical